TNGX FY 2025 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$62M+48.3% YoY

Gross Profit

$00.0% margin

Operating Income

-$111M-178.4% margin

Net Income

-$102M-162.9% margin

EPS (Diluted)

$-0.87

Cash Flow

Operating Cash Flow

-$139M

Free Cash Flow

-$140M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$399M

Total Liabilities

$53M

Stockholders' Equity

$346M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$62M	$42M	+48.3%
Gross Profit	$0	$42M	-100.0%
Operating Income	-$111M	-$146M	+23.6%
Net Income	-$102M	-$130M	+22.0%